Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (HKG:9989)

HKG:9989 Revenue

Shenzhen Hepalink Pharmaceutical Group had revenue of 1.23B CNY in the quarter ending September 30, 2024, a decrease of -8.80%. This brings the company's revenue in the last twelve months to 5.45B, down -6.46% year-over-year. In the year 2023, Shenzhen Hepalink Pharmaceutical Group had annual revenue of 5.45B, down -23.94%.

• Revenue (ttm): 5.45B CNY
• Revenue Growth: -6.46%
• P/S Ratio: n/a
• Revenue / Employee: 2.62M CNY
• Employees: 2,080
• Market Cap: 16.09B HKD

Revenue Chart

* This company reports financials in CNY.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	5.45B	-1.71B	-23.94%
Jan 1, 2023	7.16B	794.23M	12.48%
Jan 1, 2022	6.37B	1.03B	19.38%
Dec 31, 2020	5.33B	707.42M	15.30%
Dec 31, 2019	4.62B	-190.31M	-3.95%